Global Single-Domain Heavy Chain Antibody Supply, Demand and Key Producers, 2026-2032
The global Single-Domain Heavy Chain Antibody market size is expected to reach $ 3367 million by 2032, rising at a market growth of 16.5% CAGR during the forecast period (2026-2032).
Single-Domain Heavy Chain Antibody refers to a small antibody molecule in which a single variable domain can recognize and bind to an antigen. In industry usage, it is more commonly described as Single-Domain Antibody, VHH Antibody, or sdAb, covering camelid-derived VHH antibodies, shark-derived VNAR antibodies, and engineered human VH single-domain antibodies. Compared with conventional full-length IgG antibodies, these molecules are smaller, structurally simpler, and generally more stable, with good tissue penetration and strong engineering flexibility. They can be used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, cell therapy binding domains, and bispecific or multispecific antibody development. Key upstream inputs include antigen proteins or peptides, immunized animal resources, phage display libraries, yeast display libraries, synthetic antibody libraries, expression vectors, host cells, culture media, chromatography resins, conjugation reagents, and protein purification consumables. Major downstream customers include pharmaceutical companies, biotechnology companies, diagnostic companies, research service providers, universities, research institutes, and hospital laboratories. The global industry gross margin in 2025 is estimated at approximately 55%?75%.
The single-domain heavy chain antibody market is still in a stage of continuous platform validation and accelerating commercialization, with lower maturity than the conventional monoclonal antibody market but higher innovation activity. VHH, VNAR, and engineered human VH antibodies are gaining application momentum due to their small molecular size, good stability, engineering flexibility, and stronger tissue penetration. They are increasingly used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, and cell therapy engineering. Current market participants include innovative drug developers with proprietary platforms and clinical pipelines, as well as CROs and reagent companies providing antibody discovery, screening, humanization, affinity maturation, and protein expression services. The industry remains both platform-driven and project-driven.
From the demand side, therapeutic applications represent the highest long-term value area, especially in tumor immunology, immune-mediated inflammatory diseases, rare diseases, infectious diseases, and central nervous system delivery. Compared with conventional antibodies, single-domain antibodies are well suited for bispecific, multispecific, multivalent, and fusion protein formats, and can also serve as targeting domains for CAR-T, TCR-T, and other cell therapy products. At the same time, research and diagnostic applications provide a more stable demand base. Single-domain antibodies are well adapted for immunoassays, tissue staining, structural biology, live-cell imaging, and protein localization studies, supporting commercial demand before broader therapeutic commercialization.
Future development will focus on fully human platforms, multispecific design, half-life extension, AI-assisted screening, and high-throughput antibody library construction. The small size of single-domain antibodies is both an advantage and a limitation, as it can lead to faster in vivo clearance. As a result, albumin binding, Fc fusion, multivalent formatting, and PEGylation will remain important half-life extension strategies. With the integration of AI protein design, deep sequencing, synthetic antibody libraries, phage display, and yeast display technologies, discovery efficiency and developability assessment are expected to improve. Companies with strong capabilities in difficult-target screening, multi-format antibody engineering, CMC scale-up, and clinical translation will be better positioned in high-value therapeutic programs.
The main barriers include long clinical validation cycles, intellectual property constraints, immunogenicity control, manufacturing scale-up, and increasing service-level competition. Some VHH and VNAR molecules originate from non-human species, requiring sufficient humanization and immunogenicity assessment before therapeutic development. The short half-life associated with small molecular size also requires additional engineering, increasing R&D complexity. Meanwhile, as more CROs, research reagent suppliers, and platform companies enter VHH and sdAb discovery services, early-stage service pricing pressure may intensify. Overall, single-domain heavy chain antibodies are unlikely to simply replace conventional monoclonal antibodies, but they will continue to expand in differentiated scenarios such as difficult targets, multispecific formats, tissue penetration, imaging diagnostics, and cell therapy engineering.
This report studies the global Single-Domain Heavy Chain Antibody demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Single-Domain Heavy Chain Antibody, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Single-Domain Heavy Chain Antibody that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Single-Domain Heavy Chain Antibody total market, 2021-2032, (USD Million)
Global Single-Domain Heavy Chain Antibody total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Single-Domain Heavy Chain Antibody total market, key domestic companies, and share, (USD Million)
Global Single-Domain Heavy Chain Antibody revenue by player, revenue and market share 2021-2026, (USD Million)
Global Single-Domain Heavy Chain Antibody total market by Type, CAGR, 2021-2032, (USD Million)
Global Single-Domain Heavy Chain Antibody total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Single-Domain Heavy Chain Antibody market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, MoonLake Immunotherapeutics, Crescendo Biologics, Ossianix, Isogenica, FairJourney Biologics, Twist Bioscience, RayBiotech, Fortis Life Sciences, AlpVHHs, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Single-Domain Heavy Chain Antibody market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Single-Domain Heavy Chain Antibody Market, By Region:
1. How big is the global Single-Domain Heavy Chain Antibody market?
2. What is the demand of the global Single-Domain Heavy Chain Antibody market?
3. What is the year over year growth of the global Single-Domain Heavy Chain Antibody market?
4. What is the total value of the global Single-Domain Heavy Chain Antibody market?
5. Who are the Major Players in the global Single-Domain Heavy Chain Antibody market?
6. What are the growth factors driving the market demand?
Single-Domain Heavy Chain Antibody refers to a small antibody molecule in which a single variable domain can recognize and bind to an antigen. In industry usage, it is more commonly described as Single-Domain Antibody, VHH Antibody, or sdAb, covering camelid-derived VHH antibodies, shark-derived VNAR antibodies, and engineered human VH single-domain antibodies. Compared with conventional full-length IgG antibodies, these molecules are smaller, structurally simpler, and generally more stable, with good tissue penetration and strong engineering flexibility. They can be used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, cell therapy binding domains, and bispecific or multispecific antibody development. Key upstream inputs include antigen proteins or peptides, immunized animal resources, phage display libraries, yeast display libraries, synthetic antibody libraries, expression vectors, host cells, culture media, chromatography resins, conjugation reagents, and protein purification consumables. Major downstream customers include pharmaceutical companies, biotechnology companies, diagnostic companies, research service providers, universities, research institutes, and hospital laboratories. The global industry gross margin in 2025 is estimated at approximately 55%?75%.
The single-domain heavy chain antibody market is still in a stage of continuous platform validation and accelerating commercialization, with lower maturity than the conventional monoclonal antibody market but higher innovation activity. VHH, VNAR, and engineered human VH antibodies are gaining application momentum due to their small molecular size, good stability, engineering flexibility, and stronger tissue penetration. They are increasingly used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, and cell therapy engineering. Current market participants include innovative drug developers with proprietary platforms and clinical pipelines, as well as CROs and reagent companies providing antibody discovery, screening, humanization, affinity maturation, and protein expression services. The industry remains both platform-driven and project-driven.
From the demand side, therapeutic applications represent the highest long-term value area, especially in tumor immunology, immune-mediated inflammatory diseases, rare diseases, infectious diseases, and central nervous system delivery. Compared with conventional antibodies, single-domain antibodies are well suited for bispecific, multispecific, multivalent, and fusion protein formats, and can also serve as targeting domains for CAR-T, TCR-T, and other cell therapy products. At the same time, research and diagnostic applications provide a more stable demand base. Single-domain antibodies are well adapted for immunoassays, tissue staining, structural biology, live-cell imaging, and protein localization studies, supporting commercial demand before broader therapeutic commercialization.
Future development will focus on fully human platforms, multispecific design, half-life extension, AI-assisted screening, and high-throughput antibody library construction. The small size of single-domain antibodies is both an advantage and a limitation, as it can lead to faster in vivo clearance. As a result, albumin binding, Fc fusion, multivalent formatting, and PEGylation will remain important half-life extension strategies. With the integration of AI protein design, deep sequencing, synthetic antibody libraries, phage display, and yeast display technologies, discovery efficiency and developability assessment are expected to improve. Companies with strong capabilities in difficult-target screening, multi-format antibody engineering, CMC scale-up, and clinical translation will be better positioned in high-value therapeutic programs.
The main barriers include long clinical validation cycles, intellectual property constraints, immunogenicity control, manufacturing scale-up, and increasing service-level competition. Some VHH and VNAR molecules originate from non-human species, requiring sufficient humanization and immunogenicity assessment before therapeutic development. The short half-life associated with small molecular size also requires additional engineering, increasing R&D complexity. Meanwhile, as more CROs, research reagent suppliers, and platform companies enter VHH and sdAb discovery services, early-stage service pricing pressure may intensify. Overall, single-domain heavy chain antibodies are unlikely to simply replace conventional monoclonal antibodies, but they will continue to expand in differentiated scenarios such as difficult targets, multispecific formats, tissue penetration, imaging diagnostics, and cell therapy engineering.
This report studies the global Single-Domain Heavy Chain Antibody demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Single-Domain Heavy Chain Antibody, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Single-Domain Heavy Chain Antibody that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Single-Domain Heavy Chain Antibody total market, 2021-2032, (USD Million)
Global Single-Domain Heavy Chain Antibody total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Single-Domain Heavy Chain Antibody total market, key domestic companies, and share, (USD Million)
Global Single-Domain Heavy Chain Antibody revenue by player, revenue and market share 2021-2026, (USD Million)
Global Single-Domain Heavy Chain Antibody total market by Type, CAGR, 2021-2032, (USD Million)
Global Single-Domain Heavy Chain Antibody total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Single-Domain Heavy Chain Antibody market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, MoonLake Immunotherapeutics, Crescendo Biologics, Ossianix, Isogenica, FairJourney Biologics, Twist Bioscience, RayBiotech, Fortis Life Sciences, AlpVHHs, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Single-Domain Heavy Chain Antibody market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Single-Domain Heavy Chain Antibody Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Camelid-Derived
- Shark-Derived
- Fully Human Platform
- Other
- VHH Antibody
- VNAR Antibody
- Human VH Antibody
- Other
- Oncology
- Immunology and Inflammation
- Neurology
- Other
- Pharmaceutical Companies
- Biotechnology Companies
- Other
- Sanofi
- MoonLake Immunotherapeutics
- Crescendo Biologics
- Ossianix
- Isogenica
- FairJourney Biologics
- Twist Bioscience
- RayBiotech
- Fortis Life Sciences
- AlpVHHs
- ProteoGenix
- Hybrigenics Services
- Sanyo Fine
- WuXi Biologics
- Harbour BioMed
- Biocytogen
- Sino Biological
- Biointron
- Novamab
- Creative Biolabs
1. How big is the global Single-Domain Heavy Chain Antibody market?
2. What is the demand of the global Single-Domain Heavy Chain Antibody market?
3. What is the year over year growth of the global Single-Domain Heavy Chain Antibody market?
4. What is the total value of the global Single-Domain Heavy Chain Antibody market?
5. Who are the Major Players in the global Single-Domain Heavy Chain Antibody market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Single-Domain Heavy Chain Antibody Introduction
1.2 World Single-Domain Heavy Chain Antibody Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Single-Domain Heavy Chain Antibody Total Market by Region (by Headquarter Location)
1.3.1 World Single-Domain Heavy Chain Antibody Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.3 China Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.4 Europe Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.5 Japan Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.6 South Korea Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.7 ASEAN Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.8 India Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Single-Domain Heavy Chain Antibody Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.2 World Single-Domain Heavy Chain Antibody Consumption Value by Region
2.2.1 World Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026)
2.2.2 World Single-Domain Heavy Chain Antibody Consumption Value Forecast by Region (2027-2032)
2.3 United States Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.4 China Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.5 Europe Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.6 Japan Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.7 South Korea Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.8 ASEAN Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.9 India Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
3 WORLD SINGLE-DOMAIN HEAVY CHAIN ANTIBODY COMPANIES COMPETITIVE ANALYSIS
3.1 World Single-Domain Heavy Chain Antibody Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Single-Domain Heavy Chain Antibody Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Single-Domain Heavy Chain Antibody in 2025
3.2.3 Global Concentration Ratios (CR8) for Single-Domain Heavy Chain Antibody in 2025
3.3 Single-Domain Heavy Chain Antibody Company Evaluation Quadrant
3.4 Single-Domain Heavy Chain Antibody Market: Overall Company Footprint Analysis
3.4.1 Single-Domain Heavy Chain Antibody Market: Region Footprint
3.4.2 Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
3.4.3 Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Single-Domain Heavy Chain Antibody Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Single-Domain Heavy Chain Antibody Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Single-Domain Heavy Chain Antibody Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Single-Domain Heavy Chain Antibody Consumption Value Comparison
4.2.1 United States VS China: Single-Domain Heavy Chain Antibody Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Single-Domain Heavy Chain Antibody Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Single-Domain Heavy Chain Antibody Companies and Market Share, 2021-2026
4.3.1 United States Based Single-Domain Heavy Chain Antibody Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026)
4.4 China Based Companies Single-Domain Heavy Chain Antibody Revenue and Market Share, 2021-2026
4.4.1 China Based Single-Domain Heavy Chain Antibody Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026)
4.5 Rest of World Based Single-Domain Heavy Chain Antibody Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Single-Domain Heavy Chain Antibody Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Single-Domain Heavy Chain Antibody Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Camelid-Derived
5.2.2 Shark-Derived
5.2.3 Fully Human Platform
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Single-Domain Heavy Chain Antibody Market Size by Type (2021-2026)
5.3.2 World Single-Domain Heavy Chain Antibody Market Size by Type (2027-2032)
5.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ANTIBODY FORMAT
6.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Antibody Format: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Antibody Format
6.2.1 VHH Antibody
6.2.2 VNAR Antibody
6.2.3 Human VH Antibody
6.2.4 Other
6.3 Market Segment by Antibody Format
6.3.1 World Single-Domain Heavy Chain Antibody Market Size by Antibody Format (2021-2026)
6.3.2 World Single-Domain Heavy Chain Antibody Market Size by Antibody Format (2027-2032)
6.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Antibody Format (2027-2032)
7 MARKET ANALYSIS BY THERAPEUTIC AREA
7.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Therapeutic Area: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Therapeutic Area
7.2.1 Oncology
7.2.2 Immunology and Inflammation
7.2.3 Neurology
7.2.4 Other
7.3 Market Segment by Therapeutic Area
7.3.1 World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area (2021-2026)
7.3.2 World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area (2027-2032)
7.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Therapeutic Area (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical Companies
8.2.2 Biotechnology Companies
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Single-Domain Heavy Chain Antibody Market Size by Application (2021-2026)
8.3.2 World Single-Domain Heavy Chain Antibody Market Size by Application (2027-2032)
8.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Sanofi
9.1.1 Sanofi Details
9.1.2 Sanofi Major Business
9.1.3 Sanofi Single-Domain Heavy Chain Antibody Product and Services
9.1.4 Sanofi Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Sanofi Recent Developments/Updates
9.1.6 Sanofi Competitive Strengths & Weaknesses
9.2 MoonLake Immunotherapeutics
9.2.1 MoonLake Immunotherapeutics Details
9.2.2 MoonLake Immunotherapeutics Major Business
9.2.3 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Services
9.2.4 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 MoonLake Immunotherapeutics Recent Developments/Updates
9.2.6 MoonLake Immunotherapeutics Competitive Strengths & Weaknesses
9.3 Crescendo Biologics
9.3.1 Crescendo Biologics Details
9.3.2 Crescendo Biologics Major Business
9.3.3 Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Services
9.3.4 Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Crescendo Biologics Recent Developments/Updates
9.3.6 Crescendo Biologics Competitive Strengths & Weaknesses
9.4 Ossianix
9.4.1 Ossianix Details
9.4.2 Ossianix Major Business
9.4.3 Ossianix Single-Domain Heavy Chain Antibody Product and Services
9.4.4 Ossianix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Ossianix Recent Developments/Updates
9.4.6 Ossianix Competitive Strengths & Weaknesses
9.5 Isogenica
9.5.1 Isogenica Details
9.5.2 Isogenica Major Business
9.5.3 Isogenica Single-Domain Heavy Chain Antibody Product and Services
9.5.4 Isogenica Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Isogenica Recent Developments/Updates
9.5.6 Isogenica Competitive Strengths & Weaknesses
9.6 FairJourney Biologics
9.6.1 FairJourney Biologics Details
9.6.2 FairJourney Biologics Major Business
9.6.3 FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Services
9.6.4 FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 FairJourney Biologics Recent Developments/Updates
9.6.6 FairJourney Biologics Competitive Strengths & Weaknesses
9.7 Twist Bioscience
9.7.1 Twist Bioscience Details
9.7.2 Twist Bioscience Major Business
9.7.3 Twist Bioscience Single-Domain Heavy Chain Antibody Product and Services
9.7.4 Twist Bioscience Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Twist Bioscience Recent Developments/Updates
9.7.6 Twist Bioscience Competitive Strengths & Weaknesses
9.8 RayBiotech
9.8.1 RayBiotech Details
9.8.2 RayBiotech Major Business
9.8.3 RayBiotech Single-Domain Heavy Chain Antibody Product and Services
9.8.4 RayBiotech Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 RayBiotech Recent Developments/Updates
9.8.6 RayBiotech Competitive Strengths & Weaknesses
9.9 Fortis Life Sciences
9.9.1 Fortis Life Sciences Details
9.9.2 Fortis Life Sciences Major Business
9.9.3 Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Services
9.9.4 Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Fortis Life Sciences Recent Developments/Updates
9.9.6 Fortis Life Sciences Competitive Strengths & Weaknesses
9.10 AlpVHHs
9.10.1 AlpVHHs Details
9.10.2 AlpVHHs Major Business
9.10.3 AlpVHHs Single-Domain Heavy Chain Antibody Product and Services
9.10.4 AlpVHHs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 AlpVHHs Recent Developments/Updates
9.10.6 AlpVHHs Competitive Strengths & Weaknesses
9.11 ProteoGenix
9.11.1 ProteoGenix Details
9.11.2 ProteoGenix Major Business
9.11.3 ProteoGenix Single-Domain Heavy Chain Antibody Product and Services
9.11.4 ProteoGenix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 ProteoGenix Recent Developments/Updates
9.11.6 ProteoGenix Competitive Strengths & Weaknesses
9.12 Hybrigenics Services
9.12.1 Hybrigenics Services Details
9.12.2 Hybrigenics Services Major Business
9.12.3 Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Services
9.12.4 Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Hybrigenics Services Recent Developments/Updates
9.12.6 Hybrigenics Services Competitive Strengths & Weaknesses
9.13 Sanyo Fine
9.13.1 Sanyo Fine Details
9.13.2 Sanyo Fine Major Business
9.13.3 Sanyo Fine Single-Domain Heavy Chain Antibody Product and Services
9.13.4 Sanyo Fine Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Sanyo Fine Recent Developments/Updates
9.13.6 Sanyo Fine Competitive Strengths & Weaknesses
9.14 WuXi Biologics
9.14.1 WuXi Biologics Details
9.14.2 WuXi Biologics Major Business
9.14.3 WuXi Biologics Single-Domain Heavy Chain Antibody Product and Services
9.14.4 WuXi Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 WuXi Biologics Recent Developments/Updates
9.14.6 WuXi Biologics Competitive Strengths & Weaknesses
9.15 Harbour BioMed
9.15.1 Harbour BioMed Details
9.15.2 Harbour BioMed Major Business
9.15.3 Harbour BioMed Single-Domain Heavy Chain Antibody Product and Services
9.15.4 Harbour BioMed Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Harbour BioMed Recent Developments/Updates
9.15.6 Harbour BioMed Competitive Strengths & Weaknesses
9.16 Biocytogen
9.16.1 Biocytogen Details
9.16.2 Biocytogen Major Business
9.16.3 Biocytogen Single-Domain Heavy Chain Antibody Product and Services
9.16.4 Biocytogen Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Biocytogen Recent Developments/Updates
9.16.6 Biocytogen Competitive Strengths & Weaknesses
9.17 Sino Biological
9.17.1 Sino Biological Details
9.17.2 Sino Biological Major Business
9.17.3 Sino Biological Single-Domain Heavy Chain Antibody Product and Services
9.17.4 Sino Biological Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Sino Biological Recent Developments/Updates
9.17.6 Sino Biological Competitive Strengths & Weaknesses
9.18 Biointron
9.18.1 Biointron Details
9.18.2 Biointron Major Business
9.18.3 Biointron Single-Domain Heavy Chain Antibody Product and Services
9.18.4 Biointron Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Biointron Recent Developments/Updates
9.18.6 Biointron Competitive Strengths & Weaknesses
9.19 Novamab
9.19.1 Novamab Details
9.19.2 Novamab Major Business
9.19.3 Novamab Single-Domain Heavy Chain Antibody Product and Services
9.19.4 Novamab Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Novamab Recent Developments/Updates
9.19.6 Novamab Competitive Strengths & Weaknesses
9.20 Creative Biolabs
9.20.1 Creative Biolabs Details
9.20.2 Creative Biolabs Major Business
9.20.3 Creative Biolabs Single-Domain Heavy Chain Antibody Product and Services
9.20.4 Creative Biolabs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Creative Biolabs Recent Developments/Updates
9.20.6 Creative Biolabs Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Single-Domain Heavy Chain Antibody Industry Chain
10.2 Single-Domain Heavy Chain Antibody Upstream Analysis
10.3 Single-Domain Heavy Chain Antibody Midstream Analysis
10.4 Single-Domain Heavy Chain Antibody Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Single-Domain Heavy Chain Antibody Introduction
1.2 World Single-Domain Heavy Chain Antibody Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Single-Domain Heavy Chain Antibody Total Market by Region (by Headquarter Location)
1.3.1 World Single-Domain Heavy Chain Antibody Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.3 China Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.4 Europe Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.5 Japan Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.6 South Korea Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.7 ASEAN Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.3.8 India Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Single-Domain Heavy Chain Antibody Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.2 World Single-Domain Heavy Chain Antibody Consumption Value by Region
2.2.1 World Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026)
2.2.2 World Single-Domain Heavy Chain Antibody Consumption Value Forecast by Region (2027-2032)
2.3 United States Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.4 China Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.5 Europe Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.6 Japan Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.7 South Korea Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.8 ASEAN Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
2.9 India Single-Domain Heavy Chain Antibody Consumption Value (2021-2032)
3 WORLD SINGLE-DOMAIN HEAVY CHAIN ANTIBODY COMPANIES COMPETITIVE ANALYSIS
3.1 World Single-Domain Heavy Chain Antibody Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Single-Domain Heavy Chain Antibody Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Single-Domain Heavy Chain Antibody in 2025
3.2.3 Global Concentration Ratios (CR8) for Single-Domain Heavy Chain Antibody in 2025
3.3 Single-Domain Heavy Chain Antibody Company Evaluation Quadrant
3.4 Single-Domain Heavy Chain Antibody Market: Overall Company Footprint Analysis
3.4.1 Single-Domain Heavy Chain Antibody Market: Region Footprint
3.4.2 Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
3.4.3 Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Single-Domain Heavy Chain Antibody Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Single-Domain Heavy Chain Antibody Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Single-Domain Heavy Chain Antibody Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Single-Domain Heavy Chain Antibody Consumption Value Comparison
4.2.1 United States VS China: Single-Domain Heavy Chain Antibody Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Single-Domain Heavy Chain Antibody Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Single-Domain Heavy Chain Antibody Companies and Market Share, 2021-2026
4.3.1 United States Based Single-Domain Heavy Chain Antibody Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026)
4.4 China Based Companies Single-Domain Heavy Chain Antibody Revenue and Market Share, 2021-2026
4.4.1 China Based Single-Domain Heavy Chain Antibody Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026)
4.5 Rest of World Based Single-Domain Heavy Chain Antibody Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Single-Domain Heavy Chain Antibody Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Single-Domain Heavy Chain Antibody Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Camelid-Derived
5.2.2 Shark-Derived
5.2.3 Fully Human Platform
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Single-Domain Heavy Chain Antibody Market Size by Type (2021-2026)
5.3.2 World Single-Domain Heavy Chain Antibody Market Size by Type (2027-2032)
5.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ANTIBODY FORMAT
6.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Antibody Format: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Antibody Format
6.2.1 VHH Antibody
6.2.2 VNAR Antibody
6.2.3 Human VH Antibody
6.2.4 Other
6.3 Market Segment by Antibody Format
6.3.1 World Single-Domain Heavy Chain Antibody Market Size by Antibody Format (2021-2026)
6.3.2 World Single-Domain Heavy Chain Antibody Market Size by Antibody Format (2027-2032)
6.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Antibody Format (2027-2032)
7 MARKET ANALYSIS BY THERAPEUTIC AREA
7.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Therapeutic Area: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Therapeutic Area
7.2.1 Oncology
7.2.2 Immunology and Inflammation
7.2.3 Neurology
7.2.4 Other
7.3 Market Segment by Therapeutic Area
7.3.1 World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area (2021-2026)
7.3.2 World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area (2027-2032)
7.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Therapeutic Area (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Single-Domain Heavy Chain Antibody Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical Companies
8.2.2 Biotechnology Companies
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Single-Domain Heavy Chain Antibody Market Size by Application (2021-2026)
8.3.2 World Single-Domain Heavy Chain Antibody Market Size by Application (2027-2032)
8.3.3 World Single-Domain Heavy Chain Antibody Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Sanofi
9.1.1 Sanofi Details
9.1.2 Sanofi Major Business
9.1.3 Sanofi Single-Domain Heavy Chain Antibody Product and Services
9.1.4 Sanofi Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Sanofi Recent Developments/Updates
9.1.6 Sanofi Competitive Strengths & Weaknesses
9.2 MoonLake Immunotherapeutics
9.2.1 MoonLake Immunotherapeutics Details
9.2.2 MoonLake Immunotherapeutics Major Business
9.2.3 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Services
9.2.4 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 MoonLake Immunotherapeutics Recent Developments/Updates
9.2.6 MoonLake Immunotherapeutics Competitive Strengths & Weaknesses
9.3 Crescendo Biologics
9.3.1 Crescendo Biologics Details
9.3.2 Crescendo Biologics Major Business
9.3.3 Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Services
9.3.4 Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Crescendo Biologics Recent Developments/Updates
9.3.6 Crescendo Biologics Competitive Strengths & Weaknesses
9.4 Ossianix
9.4.1 Ossianix Details
9.4.2 Ossianix Major Business
9.4.3 Ossianix Single-Domain Heavy Chain Antibody Product and Services
9.4.4 Ossianix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Ossianix Recent Developments/Updates
9.4.6 Ossianix Competitive Strengths & Weaknesses
9.5 Isogenica
9.5.1 Isogenica Details
9.5.2 Isogenica Major Business
9.5.3 Isogenica Single-Domain Heavy Chain Antibody Product and Services
9.5.4 Isogenica Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Isogenica Recent Developments/Updates
9.5.6 Isogenica Competitive Strengths & Weaknesses
9.6 FairJourney Biologics
9.6.1 FairJourney Biologics Details
9.6.2 FairJourney Biologics Major Business
9.6.3 FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Services
9.6.4 FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 FairJourney Biologics Recent Developments/Updates
9.6.6 FairJourney Biologics Competitive Strengths & Weaknesses
9.7 Twist Bioscience
9.7.1 Twist Bioscience Details
9.7.2 Twist Bioscience Major Business
9.7.3 Twist Bioscience Single-Domain Heavy Chain Antibody Product and Services
9.7.4 Twist Bioscience Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Twist Bioscience Recent Developments/Updates
9.7.6 Twist Bioscience Competitive Strengths & Weaknesses
9.8 RayBiotech
9.8.1 RayBiotech Details
9.8.2 RayBiotech Major Business
9.8.3 RayBiotech Single-Domain Heavy Chain Antibody Product and Services
9.8.4 RayBiotech Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 RayBiotech Recent Developments/Updates
9.8.6 RayBiotech Competitive Strengths & Weaknesses
9.9 Fortis Life Sciences
9.9.1 Fortis Life Sciences Details
9.9.2 Fortis Life Sciences Major Business
9.9.3 Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Services
9.9.4 Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Fortis Life Sciences Recent Developments/Updates
9.9.6 Fortis Life Sciences Competitive Strengths & Weaknesses
9.10 AlpVHHs
9.10.1 AlpVHHs Details
9.10.2 AlpVHHs Major Business
9.10.3 AlpVHHs Single-Domain Heavy Chain Antibody Product and Services
9.10.4 AlpVHHs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 AlpVHHs Recent Developments/Updates
9.10.6 AlpVHHs Competitive Strengths & Weaknesses
9.11 ProteoGenix
9.11.1 ProteoGenix Details
9.11.2 ProteoGenix Major Business
9.11.3 ProteoGenix Single-Domain Heavy Chain Antibody Product and Services
9.11.4 ProteoGenix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 ProteoGenix Recent Developments/Updates
9.11.6 ProteoGenix Competitive Strengths & Weaknesses
9.12 Hybrigenics Services
9.12.1 Hybrigenics Services Details
9.12.2 Hybrigenics Services Major Business
9.12.3 Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Services
9.12.4 Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Hybrigenics Services Recent Developments/Updates
9.12.6 Hybrigenics Services Competitive Strengths & Weaknesses
9.13 Sanyo Fine
9.13.1 Sanyo Fine Details
9.13.2 Sanyo Fine Major Business
9.13.3 Sanyo Fine Single-Domain Heavy Chain Antibody Product and Services
9.13.4 Sanyo Fine Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Sanyo Fine Recent Developments/Updates
9.13.6 Sanyo Fine Competitive Strengths & Weaknesses
9.14 WuXi Biologics
9.14.1 WuXi Biologics Details
9.14.2 WuXi Biologics Major Business
9.14.3 WuXi Biologics Single-Domain Heavy Chain Antibody Product and Services
9.14.4 WuXi Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 WuXi Biologics Recent Developments/Updates
9.14.6 WuXi Biologics Competitive Strengths & Weaknesses
9.15 Harbour BioMed
9.15.1 Harbour BioMed Details
9.15.2 Harbour BioMed Major Business
9.15.3 Harbour BioMed Single-Domain Heavy Chain Antibody Product and Services
9.15.4 Harbour BioMed Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Harbour BioMed Recent Developments/Updates
9.15.6 Harbour BioMed Competitive Strengths & Weaknesses
9.16 Biocytogen
9.16.1 Biocytogen Details
9.16.2 Biocytogen Major Business
9.16.3 Biocytogen Single-Domain Heavy Chain Antibody Product and Services
9.16.4 Biocytogen Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Biocytogen Recent Developments/Updates
9.16.6 Biocytogen Competitive Strengths & Weaknesses
9.17 Sino Biological
9.17.1 Sino Biological Details
9.17.2 Sino Biological Major Business
9.17.3 Sino Biological Single-Domain Heavy Chain Antibody Product and Services
9.17.4 Sino Biological Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Sino Biological Recent Developments/Updates
9.17.6 Sino Biological Competitive Strengths & Weaknesses
9.18 Biointron
9.18.1 Biointron Details
9.18.2 Biointron Major Business
9.18.3 Biointron Single-Domain Heavy Chain Antibody Product and Services
9.18.4 Biointron Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Biointron Recent Developments/Updates
9.18.6 Biointron Competitive Strengths & Weaknesses
9.19 Novamab
9.19.1 Novamab Details
9.19.2 Novamab Major Business
9.19.3 Novamab Single-Domain Heavy Chain Antibody Product and Services
9.19.4 Novamab Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Novamab Recent Developments/Updates
9.19.6 Novamab Competitive Strengths & Weaknesses
9.20 Creative Biolabs
9.20.1 Creative Biolabs Details
9.20.2 Creative Biolabs Major Business
9.20.3 Creative Biolabs Single-Domain Heavy Chain Antibody Product and Services
9.20.4 Creative Biolabs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Creative Biolabs Recent Developments/Updates
9.20.6 Creative Biolabs Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Single-Domain Heavy Chain Antibody Industry Chain
10.2 Single-Domain Heavy Chain Antibody Upstream Analysis
10.3 Single-Domain Heavy Chain Antibody Midstream Analysis
10.4 Single-Domain Heavy Chain Antibody Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Single-Domain Heavy Chain Antibody Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Single-Domain Heavy Chain Antibody Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Single-Domain Heavy Chain Antibody Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Single-Domain Heavy Chain Antibody Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Single-Domain Heavy Chain Antibody Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Single-Domain Heavy Chain Antibody Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Single-Domain Heavy Chain Antibody Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Single-Domain Heavy Chain Antibody Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Single-Domain Heavy Chain Antibody Players in 2025
Table 12. World Single-Domain Heavy Chain Antibody Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Single-Domain Heavy Chain Antibody Company Evaluation Quadrant
Table 14. Head Office of Key Single-Domain Heavy Chain Antibody Players
Table 15. Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
Table 16. Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
Table 17. Single-Domain Heavy Chain Antibody Mergers & Acquisitions Activity
Table 18. United States VS China Single-Domain Heavy Chain Antibody Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Single-Domain Heavy Chain Antibody Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Single-Domain Heavy Chain Antibody Companies, Headquarters (States, Country)
Table 21. United States Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Single-Domain Heavy Chain Antibody Revenue Market Share (2021-2026)
Table 23. China Based Single-Domain Heavy Chain Antibody Companies, Headquarters (Province, Country)
Table 24. China Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Single-Domain Heavy Chain Antibody Revenue Market Share (2021-2026)
Table 26. Rest of World Based Single-Domain Heavy Chain Antibody Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Single-Domain Heavy Chain Antibody Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Single-Domain Heavy Chain Antibody Revenue Market Share (2021-2026)
Table 29. World Single-Domain Heavy Chain Antibody Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Single-Domain Heavy Chain Antibody Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Single-Domain Heavy Chain Antibody Market Size by Type (2027-2032) & (USD Million)
Table 32. World Single-Domain Heavy Chain Antibody Market Size by Antibody Format, (USD Million), 2021 & 2025 & 2032
Table 33. World Single-Domain Heavy Chain Antibody Market Size Value by Antibody Format (2021-2026) & (USD Million)
Table 34. World Single-Domain Heavy Chain Antibody Market Size by Antibody Format (2027-2032) & (USD Million)
Table 35. World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Table 36. World Single-Domain Heavy Chain Antibody Market Size Value by Therapeutic Area (2021-2026) & (USD Million)
Table 37. World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area (2027-2032) & (USD Million)
Table 38. World Single-Domain Heavy Chain Antibody Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Single-Domain Heavy Chain Antibody Market Size by Application (2021-2026) & (USD Million)
Table 40. World Single-Domain Heavy Chain Antibody Market Size by Application (2027-2032) & (USD Million)
Table 41. Sanofi Basic Information, Manufacturing Base and Competitors
Table 42. Sanofi Major Business
Table 43. Sanofi Single-Domain Heavy Chain Antibody Product and Services
Table 44. Sanofi Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Sanofi Recent Developments/Updates
Table 46. Sanofi Competitive Strengths & Weaknesses
Table 47. MoonLake Immunotherapeutics Basic Information, Manufacturing Base and Competitors
Table 48. MoonLake Immunotherapeutics Major Business
Table 49. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Services
Table 50. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. MoonLake Immunotherapeutics Recent Developments/Updates
Table 52. MoonLake Immunotherapeutics Competitive Strengths & Weaknesses
Table 53. Crescendo Biologics Basic Information, Manufacturing Base and Competitors
Table 54. Crescendo Biologics Major Business
Table 55. Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Services
Table 56. Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Crescendo Biologics Recent Developments/Updates
Table 58. Crescendo Biologics Competitive Strengths & Weaknesses
Table 59. Ossianix Basic Information, Manufacturing Base and Competitors
Table 60. Ossianix Major Business
Table 61. Ossianix Single-Domain Heavy Chain Antibody Product and Services
Table 62. Ossianix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Ossianix Recent Developments/Updates
Table 64. Ossianix Competitive Strengths & Weaknesses
Table 65. Isogenica Basic Information, Manufacturing Base and Competitors
Table 66. Isogenica Major Business
Table 67. Isogenica Single-Domain Heavy Chain Antibody Product and Services
Table 68. Isogenica Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Isogenica Recent Developments/Updates
Table 70. Isogenica Competitive Strengths & Weaknesses
Table 71. FairJourney Biologics Basic Information, Manufacturing Base and Competitors
Table 72. FairJourney Biologics Major Business
Table 73. FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Services
Table 74. FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. FairJourney Biologics Recent Developments/Updates
Table 76. FairJourney Biologics Competitive Strengths & Weaknesses
Table 77. Twist Bioscience Basic Information, Manufacturing Base and Competitors
Table 78. Twist Bioscience Major Business
Table 79. Twist Bioscience Single-Domain Heavy Chain Antibody Product and Services
Table 80. Twist Bioscience Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Twist Bioscience Recent Developments/Updates
Table 82. Twist Bioscience Competitive Strengths & Weaknesses
Table 83. RayBiotech Basic Information, Manufacturing Base and Competitors
Table 84. RayBiotech Major Business
Table 85. RayBiotech Single-Domain Heavy Chain Antibody Product and Services
Table 86. RayBiotech Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. RayBiotech Recent Developments/Updates
Table 88. RayBiotech Competitive Strengths & Weaknesses
Table 89. Fortis Life Sciences Basic Information, Manufacturing Base and Competitors
Table 90. Fortis Life Sciences Major Business
Table 91. Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Services
Table 92. Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Fortis Life Sciences Recent Developments/Updates
Table 94. Fortis Life Sciences Competitive Strengths & Weaknesses
Table 95. AlpVHHs Basic Information, Manufacturing Base and Competitors
Table 96. AlpVHHs Major Business
Table 97. AlpVHHs Single-Domain Heavy Chain Antibody Product and Services
Table 98. AlpVHHs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. AlpVHHs Recent Developments/Updates
Table 100. AlpVHHs Competitive Strengths & Weaknesses
Table 101. ProteoGenix Basic Information, Manufacturing Base and Competitors
Table 102. ProteoGenix Major Business
Table 103. ProteoGenix Single-Domain Heavy Chain Antibody Product and Services
Table 104. ProteoGenix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. ProteoGenix Recent Developments/Updates
Table 106. ProteoGenix Competitive Strengths & Weaknesses
Table 107. Hybrigenics Services Basic Information, Manufacturing Base and Competitors
Table 108. Hybrigenics Services Major Business
Table 109. Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Services
Table 110. Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Hybrigenics Services Recent Developments/Updates
Table 112. Hybrigenics Services Competitive Strengths & Weaknesses
Table 113. Sanyo Fine Basic Information, Manufacturing Base and Competitors
Table 114. Sanyo Fine Major Business
Table 115. Sanyo Fine Single-Domain Heavy Chain Antibody Product and Services
Table 116. Sanyo Fine Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Sanyo Fine Recent Developments/Updates
Table 118. Sanyo Fine Competitive Strengths & Weaknesses
Table 119. WuXi Biologics Basic Information, Manufacturing Base and Competitors
Table 120. WuXi Biologics Major Business
Table 121. WuXi Biologics Single-Domain Heavy Chain Antibody Product and Services
Table 122. WuXi Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. WuXi Biologics Recent Developments/Updates
Table 124. WuXi Biologics Competitive Strengths & Weaknesses
Table 125. Harbour BioMed Basic Information, Manufacturing Base and Competitors
Table 126. Harbour BioMed Major Business
Table 127. Harbour BioMed Single-Domain Heavy Chain Antibody Product and Services
Table 128. Harbour BioMed Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Harbour BioMed Recent Developments/Updates
Table 130. Harbour BioMed Competitive Strengths & Weaknesses
Table 131. Biocytogen Basic Information, Manufacturing Base and Competitors
Table 132. Biocytogen Major Business
Table 133. Biocytogen Single-Domain Heavy Chain Antibody Product and Services
Table 134. Biocytogen Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Biocytogen Recent Developments/Updates
Table 136. Biocytogen Competitive Strengths & Weaknesses
Table 137. Sino Biological Basic Information, Manufacturing Base and Competitors
Table 138. Sino Biological Major Business
Table 139. Sino Biological Single-Domain Heavy Chain Antibody Product and Services
Table 140. Sino Biological Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Sino Biological Recent Developments/Updates
Table 142. Sino Biological Competitive Strengths & Weaknesses
Table 143. Biointron Basic Information, Manufacturing Base and Competitors
Table 144. Biointron Major Business
Table 145. Biointron Single-Domain Heavy Chain Antibody Product and Services
Table 146. Biointron Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Biointron Recent Developments/Updates
Table 148. Biointron Competitive Strengths & Weaknesses
Table 149. Novamab Basic Information, Manufacturing Base and Competitors
Table 150. Novamab Major Business
Table 151. Novamab Single-Domain Heavy Chain Antibody Product and Services
Table 152. Novamab Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Novamab Recent Developments/Updates
Table 154. Novamab Competitive Strengths & Weaknesses
Table 155. Creative Biolabs Basic Information, Manufacturing Base and Competitors
Table 156. Creative Biolabs Major Business
Table 157. Creative Biolabs Single-Domain Heavy Chain Antibody Product and Services
Table 158. Creative Biolabs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Creative Biolabs Recent Developments/Updates
Table 160. Creative Biolabs Competitive Strengths & Weaknesses
Table 161. Global Key Players of Single-Domain Heavy Chain Antibody Upstream (Raw Materials)
Table 162. Global Single-Domain Heavy Chain Antibody Typical Customers
Table 1. World Single-Domain Heavy Chain Antibody Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Single-Domain Heavy Chain Antibody Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Single-Domain Heavy Chain Antibody Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Single-Domain Heavy Chain Antibody Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Single-Domain Heavy Chain Antibody Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Single-Domain Heavy Chain Antibody Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Single-Domain Heavy Chain Antibody Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Single-Domain Heavy Chain Antibody Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Single-Domain Heavy Chain Antibody Players in 2025
Table 12. World Single-Domain Heavy Chain Antibody Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Single-Domain Heavy Chain Antibody Company Evaluation Quadrant
Table 14. Head Office of Key Single-Domain Heavy Chain Antibody Players
Table 15. Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
Table 16. Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
Table 17. Single-Domain Heavy Chain Antibody Mergers & Acquisitions Activity
Table 18. United States VS China Single-Domain Heavy Chain Antibody Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Single-Domain Heavy Chain Antibody Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Single-Domain Heavy Chain Antibody Companies, Headquarters (States, Country)
Table 21. United States Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Single-Domain Heavy Chain Antibody Revenue Market Share (2021-2026)
Table 23. China Based Single-Domain Heavy Chain Antibody Companies, Headquarters (Province, Country)
Table 24. China Based Companies Single-Domain Heavy Chain Antibody Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Single-Domain Heavy Chain Antibody Revenue Market Share (2021-2026)
Table 26. Rest of World Based Single-Domain Heavy Chain Antibody Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Single-Domain Heavy Chain Antibody Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Single-Domain Heavy Chain Antibody Revenue Market Share (2021-2026)
Table 29. World Single-Domain Heavy Chain Antibody Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Single-Domain Heavy Chain Antibody Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Single-Domain Heavy Chain Antibody Market Size by Type (2027-2032) & (USD Million)
Table 32. World Single-Domain Heavy Chain Antibody Market Size by Antibody Format, (USD Million), 2021 & 2025 & 2032
Table 33. World Single-Domain Heavy Chain Antibody Market Size Value by Antibody Format (2021-2026) & (USD Million)
Table 34. World Single-Domain Heavy Chain Antibody Market Size by Antibody Format (2027-2032) & (USD Million)
Table 35. World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Table 36. World Single-Domain Heavy Chain Antibody Market Size Value by Therapeutic Area (2021-2026) & (USD Million)
Table 37. World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area (2027-2032) & (USD Million)
Table 38. World Single-Domain Heavy Chain Antibody Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Single-Domain Heavy Chain Antibody Market Size by Application (2021-2026) & (USD Million)
Table 40. World Single-Domain Heavy Chain Antibody Market Size by Application (2027-2032) & (USD Million)
Table 41. Sanofi Basic Information, Manufacturing Base and Competitors
Table 42. Sanofi Major Business
Table 43. Sanofi Single-Domain Heavy Chain Antibody Product and Services
Table 44. Sanofi Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Sanofi Recent Developments/Updates
Table 46. Sanofi Competitive Strengths & Weaknesses
Table 47. MoonLake Immunotherapeutics Basic Information, Manufacturing Base and Competitors
Table 48. MoonLake Immunotherapeutics Major Business
Table 49. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Services
Table 50. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. MoonLake Immunotherapeutics Recent Developments/Updates
Table 52. MoonLake Immunotherapeutics Competitive Strengths & Weaknesses
Table 53. Crescendo Biologics Basic Information, Manufacturing Base and Competitors
Table 54. Crescendo Biologics Major Business
Table 55. Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Services
Table 56. Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Crescendo Biologics Recent Developments/Updates
Table 58. Crescendo Biologics Competitive Strengths & Weaknesses
Table 59. Ossianix Basic Information, Manufacturing Base and Competitors
Table 60. Ossianix Major Business
Table 61. Ossianix Single-Domain Heavy Chain Antibody Product and Services
Table 62. Ossianix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Ossianix Recent Developments/Updates
Table 64. Ossianix Competitive Strengths & Weaknesses
Table 65. Isogenica Basic Information, Manufacturing Base and Competitors
Table 66. Isogenica Major Business
Table 67. Isogenica Single-Domain Heavy Chain Antibody Product and Services
Table 68. Isogenica Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Isogenica Recent Developments/Updates
Table 70. Isogenica Competitive Strengths & Weaknesses
Table 71. FairJourney Biologics Basic Information, Manufacturing Base and Competitors
Table 72. FairJourney Biologics Major Business
Table 73. FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Services
Table 74. FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. FairJourney Biologics Recent Developments/Updates
Table 76. FairJourney Biologics Competitive Strengths & Weaknesses
Table 77. Twist Bioscience Basic Information, Manufacturing Base and Competitors
Table 78. Twist Bioscience Major Business
Table 79. Twist Bioscience Single-Domain Heavy Chain Antibody Product and Services
Table 80. Twist Bioscience Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Twist Bioscience Recent Developments/Updates
Table 82. Twist Bioscience Competitive Strengths & Weaknesses
Table 83. RayBiotech Basic Information, Manufacturing Base and Competitors
Table 84. RayBiotech Major Business
Table 85. RayBiotech Single-Domain Heavy Chain Antibody Product and Services
Table 86. RayBiotech Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. RayBiotech Recent Developments/Updates
Table 88. RayBiotech Competitive Strengths & Weaknesses
Table 89. Fortis Life Sciences Basic Information, Manufacturing Base and Competitors
Table 90. Fortis Life Sciences Major Business
Table 91. Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Services
Table 92. Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Fortis Life Sciences Recent Developments/Updates
Table 94. Fortis Life Sciences Competitive Strengths & Weaknesses
Table 95. AlpVHHs Basic Information, Manufacturing Base and Competitors
Table 96. AlpVHHs Major Business
Table 97. AlpVHHs Single-Domain Heavy Chain Antibody Product and Services
Table 98. AlpVHHs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. AlpVHHs Recent Developments/Updates
Table 100. AlpVHHs Competitive Strengths & Weaknesses
Table 101. ProteoGenix Basic Information, Manufacturing Base and Competitors
Table 102. ProteoGenix Major Business
Table 103. ProteoGenix Single-Domain Heavy Chain Antibody Product and Services
Table 104. ProteoGenix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. ProteoGenix Recent Developments/Updates
Table 106. ProteoGenix Competitive Strengths & Weaknesses
Table 107. Hybrigenics Services Basic Information, Manufacturing Base and Competitors
Table 108. Hybrigenics Services Major Business
Table 109. Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Services
Table 110. Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Hybrigenics Services Recent Developments/Updates
Table 112. Hybrigenics Services Competitive Strengths & Weaknesses
Table 113. Sanyo Fine Basic Information, Manufacturing Base and Competitors
Table 114. Sanyo Fine Major Business
Table 115. Sanyo Fine Single-Domain Heavy Chain Antibody Product and Services
Table 116. Sanyo Fine Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Sanyo Fine Recent Developments/Updates
Table 118. Sanyo Fine Competitive Strengths & Weaknesses
Table 119. WuXi Biologics Basic Information, Manufacturing Base and Competitors
Table 120. WuXi Biologics Major Business
Table 121. WuXi Biologics Single-Domain Heavy Chain Antibody Product and Services
Table 122. WuXi Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. WuXi Biologics Recent Developments/Updates
Table 124. WuXi Biologics Competitive Strengths & Weaknesses
Table 125. Harbour BioMed Basic Information, Manufacturing Base and Competitors
Table 126. Harbour BioMed Major Business
Table 127. Harbour BioMed Single-Domain Heavy Chain Antibody Product and Services
Table 128. Harbour BioMed Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Harbour BioMed Recent Developments/Updates
Table 130. Harbour BioMed Competitive Strengths & Weaknesses
Table 131. Biocytogen Basic Information, Manufacturing Base and Competitors
Table 132. Biocytogen Major Business
Table 133. Biocytogen Single-Domain Heavy Chain Antibody Product and Services
Table 134. Biocytogen Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Biocytogen Recent Developments/Updates
Table 136. Biocytogen Competitive Strengths & Weaknesses
Table 137. Sino Biological Basic Information, Manufacturing Base and Competitors
Table 138. Sino Biological Major Business
Table 139. Sino Biological Single-Domain Heavy Chain Antibody Product and Services
Table 140. Sino Biological Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Sino Biological Recent Developments/Updates
Table 142. Sino Biological Competitive Strengths & Weaknesses
Table 143. Biointron Basic Information, Manufacturing Base and Competitors
Table 144. Biointron Major Business
Table 145. Biointron Single-Domain Heavy Chain Antibody Product and Services
Table 146. Biointron Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Biointron Recent Developments/Updates
Table 148. Biointron Competitive Strengths & Weaknesses
Table 149. Novamab Basic Information, Manufacturing Base and Competitors
Table 150. Novamab Major Business
Table 151. Novamab Single-Domain Heavy Chain Antibody Product and Services
Table 152. Novamab Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Novamab Recent Developments/Updates
Table 154. Novamab Competitive Strengths & Weaknesses
Table 155. Creative Biolabs Basic Information, Manufacturing Base and Competitors
Table 156. Creative Biolabs Major Business
Table 157. Creative Biolabs Single-Domain Heavy Chain Antibody Product and Services
Table 158. Creative Biolabs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Creative Biolabs Recent Developments/Updates
Table 160. Creative Biolabs Competitive Strengths & Weaknesses
Table 161. Global Key Players of Single-Domain Heavy Chain Antibody Upstream (Raw Materials)
Table 162. Global Single-Domain Heavy Chain Antibody Typical Customers
LIST OF FIGURES
Figure 1. Single-Domain Heavy Chain Antibody Picture
Figure 2. World Single-Domain Heavy Chain Antibody Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Single-Domain Heavy Chain Antibody Total Revenue (2021-2032) & (USD Million)
Figure 4. World Single-Domain Heavy Chain Antibody Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Single-Domain Heavy Chain Antibody Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 13. Single-Domain Heavy Chain Antibody Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 16. World Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 18. China Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 23. India Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Single-Domain Heavy Chain Antibody by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Single-Domain Heavy Chain Antibody Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Single-Domain Heavy Chain Antibody Markets in 2025
Figure 27. United States VS China: Single-Domain Heavy Chain Antibody Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Single-Domain Heavy Chain Antibody Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Single-Domain Heavy Chain Antibody Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Single-Domain Heavy Chain Antibody Market Size Market Share by Type in 2025
Figure 31. Camelid-Derived
Figure 32. Shark-Derived
Figure 33. Fully Human Platform
Figure 34. Other
Figure 35. World Single-Domain Heavy Chain Antibody Market Size Market Share by Type (2021-2032)
Figure 36. World Single-Domain Heavy Chain Antibody Market Size by Antibody Format, (USD Million), 2021 & 2025 & 2032
Figure 37. World Single-Domain Heavy Chain Antibody Market Size Market Share by Antibody Format in 2025
Figure 38. VHH Antibody
Figure 39. VNAR Antibody
Figure 40. Human VH Antibody
Figure 41. Other
Figure 42. World Single-Domain Heavy Chain Antibody Market Size Market Share by Antibody Format (2021-2032)
Figure 43. World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Figure 44. World Single-Domain Heavy Chain Antibody Market Size Market Share by Therapeutic Area in 2025
Figure 45. Oncology
Figure 46. Immunology and Inflammation
Figure 47. Neurology
Figure 48. Other
Figure 49. World Single-Domain Heavy Chain Antibody Market Size Market Share by Therapeutic Area (2021-2032)
Figure 50. World Single-Domain Heavy Chain Antibody Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Single-Domain Heavy Chain Antibody Market Size Market Share by Application in 2025
Figure 52. Pharmaceutical Companies
Figure 53. Biotechnology Companies
Figure 54. Other
Figure 55. World Single-Domain Heavy Chain Antibody Market Size Market Share by Application (2021-2032)
Figure 56. Single-Domain Heavy Chain Antibody Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source
Figure 1. Single-Domain Heavy Chain Antibody Picture
Figure 2. World Single-Domain Heavy Chain Antibody Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Single-Domain Heavy Chain Antibody Total Revenue (2021-2032) & (USD Million)
Figure 4. World Single-Domain Heavy Chain Antibody Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Single-Domain Heavy Chain Antibody Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Single-Domain Heavy Chain Antibody Revenue (2021-2032) & (USD Million)
Figure 13. Single-Domain Heavy Chain Antibody Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 16. World Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 18. China Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 23. India Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Single-Domain Heavy Chain Antibody by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Single-Domain Heavy Chain Antibody Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Single-Domain Heavy Chain Antibody Markets in 2025
Figure 27. United States VS China: Single-Domain Heavy Chain Antibody Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Single-Domain Heavy Chain Antibody Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Single-Domain Heavy Chain Antibody Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Single-Domain Heavy Chain Antibody Market Size Market Share by Type in 2025
Figure 31. Camelid-Derived
Figure 32. Shark-Derived
Figure 33. Fully Human Platform
Figure 34. Other
Figure 35. World Single-Domain Heavy Chain Antibody Market Size Market Share by Type (2021-2032)
Figure 36. World Single-Domain Heavy Chain Antibody Market Size by Antibody Format, (USD Million), 2021 & 2025 & 2032
Figure 37. World Single-Domain Heavy Chain Antibody Market Size Market Share by Antibody Format in 2025
Figure 38. VHH Antibody
Figure 39. VNAR Antibody
Figure 40. Human VH Antibody
Figure 41. Other
Figure 42. World Single-Domain Heavy Chain Antibody Market Size Market Share by Antibody Format (2021-2032)
Figure 43. World Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Figure 44. World Single-Domain Heavy Chain Antibody Market Size Market Share by Therapeutic Area in 2025
Figure 45. Oncology
Figure 46. Immunology and Inflammation
Figure 47. Neurology
Figure 48. Other
Figure 49. World Single-Domain Heavy Chain Antibody Market Size Market Share by Therapeutic Area (2021-2032)
Figure 50. World Single-Domain Heavy Chain Antibody Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Single-Domain Heavy Chain Antibody Market Size Market Share by Application in 2025
Figure 52. Pharmaceutical Companies
Figure 53. Biotechnology Companies
Figure 54. Other
Figure 55. World Single-Domain Heavy Chain Antibody Market Size Market Share by Application (2021-2032)
Figure 56. Single-Domain Heavy Chain Antibody Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source
